A Phase II/III Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET/CT Assessment.

This document provides information about a Phase II/III clinical trial being conducted in China to test the effectiveness of Brentuximab vedotin (Bv) in the treatment of newly diagnosed classical Hodgkin lymphoma (cHL) in children, adolescents, and young adults. The trial aims to increase the early assessment complete response rate and reduce the proportion of patients receiving radiation therapy. The trial is expected to be completed by November 2029. The document also includes information on the drugs and study arms used in the treatment of Hodgkin lymphoma, as well as links to relevant publications on the topic. [Extracted from the article]